News & Updates
VT-5006 is a first-in-class small molecule designed to precisely engage a validated peripheral target to delay onset and slow progression of Parkinson’s disease WOBURN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) — Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has initiated a Phase 1 study of its…
Read More
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ordinal diabetic retinopathy severity scale (DRSS) primary endpoint Targeting a broad diabetic retinopathy (DR) label by including patients with non-center-involved diabetic macular edema…
Read More
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced…
Read More
Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include an experimental arm with checkpoint inhibitor combination Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today…
Read More
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 Excerpt from the Press Release:v SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and…
Read More
Excerpt from the Press Release: PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50 patients necessary for the interim…
Read More
STMC-103H exhibited 64% reduction in the risk of atopic dermatitis in subjects who completed one year of treatment with strong and consistent effects across multiple efficacy endpoints and was safe and well-tolerated Excerpt from the Press Release: SAN CARLOS, Calif., Nov. 17, 2025 /PRNewswire/ — Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG CRO Summit in Raleigh, North Carolina. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin…
Read More
Excerpt from the Press Release: HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic…
Read More
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. – Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins. – General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?